DeepMed Research

Vall d'Hebron Research Institute

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: Private

Established: 1994-01-01

Employees: 1K

Market Cap: -

Website: http://www.vhir.org

Clinical Trials

Ribavirin for Severe Acute and Chronic Hepatitis E Virus Infection.

Phase 4

Terminated

Conditions: Hepatitis E

Interventions: Drug: Ribavirin

First Posted Date: 2015-09-23

Last Posted Date: 2019-04-16

Lead Sponsor: Hospital Universitari Vall d'Hebron Research Institute

Target Recruit Count: 5

Registration Number: NCT02558114

Locations: 🇪🇸
Hospital Universitari vall d'Hebron, Barcelona, Spain

Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla

Phase 4

Completed

Conditions: HIV-1

Interventions: Drug: efavirenz + emtricitabina + tenofovir
Drug: rilpivirina + emtricitabina + tenofovir

First Posted Date: 2015-09-11

Last Posted Date: 2017-06-14

Lead Sponsor: Hospital Universitari Vall d'Hebron Research Institute

Target Recruit Count: 30

Registration Number: NCT02547844

Locations: 🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain

Effect of Prebiotic FOS on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Crohn´s Disease

Not Applicable

Completed

Conditions: Crohn Disease

Interventions: Dietary Supplement: FOS
Drug: Adalimumab

First Posted Date: 2015-09-03

Last Posted Date: 2018-01-31

Lead Sponsor: Hospital Universitari Vall d'Hebron Research Institute

Target Recruit Count: 38

Registration Number: NCT02539849

Locations: 🇪🇸
Hospital La Princesa, Madrid, Spain
🇪🇸
Hospital de Bellvitge, Hospitalet del Llobregat, Barcelona, Spain
🇪🇸
Hospital de Santiago, Santiago de Compostela, A Coruña, Spain

and more 2 locations

Efficiency of Neurostimulation of Tibial Nerve in the Treatment of Low Anterior Resection Syndrome

Not Applicable

Completed

Conditions: Colorectal Surgery

Interventions: Device: Sham posterior tibial nerve stimulation
Device: Posterior tibial nerve stimulation

First Posted Date: 2015-08-07

Last Posted Date: 2019-11-29

Lead Sponsor: Hospital Universitari Vall d'Hebron Research Institute

Target Recruit Count: 41

Registration Number: NCT02517853

Locations: 🇪🇸
Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
🇪🇸
Hospital Vall d'Hebron, Barcelona, Spain

Contribution of Renal Function to Endothelial Dysfunction in Living Kidney Donors and Transplant Recipients

Conditions: Endothelial Dysfunction
Disorder Related to Renal Transplantation
Chronic Kidney Disease

Interventions: Other: Endothelial dysfunction

First Posted Date: 2015-08-05

Last Posted Date: 2017-03-28

Lead Sponsor: Hospital Universitari Vall d'Hebron Research Institute

Target Recruit Count: 120

Registration Number: NCT02515643

Locations: 🇪🇸
Hospital del Mar, Barcelona, Spain
🇪🇸
Hospital Universitario Canarias, Santa Cruz de Tenerife, Islas Canarias, Spain
🇪🇸
Vall d'Hebron Research Institute, Barcelona, Spain

and more 1 locations

HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen

Phase 4

Completed

Conditions: HIV-1

Interventions: Drug: PI
Drug: Dolutegravir
Drug: 2 NRTI

First Posted Date: 2015-07-31

Last Posted Date: 2017-06-14

Lead Sponsor: Hospital Universitari Vall d'Hebron Research Institute

Target Recruit Count: 44

Registration Number: NCT02513147

Locations: 🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain

Parenteral Antibiotics Compared to Combination of Oral and Parenteral Antibiotics in Colorectal Surgery Prophylaxis

Phase 4

Completed

Conditions: Surgical Wound Infection

Interventions: Drug: Extra dosage - cefuroxime (750mg) I.V
Procedure: Colorectal Surgery
Drug: Ciprofloxacin 750 mg oral
Drug: Metronidazole 250 mg oral
Drug: Cefuroxime 1.5 g Intravenous
Drug: Metronidazole 1 g Intravenous

First Posted Date: 2015-07-22

Last Posted Date: 2020-01-14

Lead Sponsor: Hospital Universitari Vall d'Hebron Research Institute

Target Recruit Count: 536

Registration Number: NCT02505581

Locations: 🇪🇸
Hospital Universitari de Girona Dr. Josep Trueta, Girona, Spain
🇪🇸
Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
🇪🇸
Hospital General Universitario Vall d´Hebron, Barcelona, Spain

"Incidence and Consequences of Disorders of Glycosylation in Patients With Conotruncal and Septal Heart Defects"

Conditions: Antithrombin III Deficiency
Congenital Heart Diseases
Conotruncal Defects
Congenital Disorder of Glycosylation

Interventions: Other: none intervention

First Posted Date: 2015-07-20

Last Posted Date: 2017-03-27

Lead Sponsor: Hospital Universitari Vall d'Hebron Research Institute

Target Recruit Count: 300

Registration Number: NCT02503267

Locations: 🇪🇸
Vall d'Hebron Hospital, Barcelona, Spain

The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)

Phase 4

Conditions: Diabetes Mellitus Type 2

Interventions: Drug: metformin
Drug: Liraglutide

First Posted Date: 2015-07-17

Last Posted Date: 2015-07-21

Lead Sponsor: Hospital Universitari Vall d'Hebron Research Institute

Target Recruit Count: 40

Registration Number: NCT02501850

Locations: 🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain

Type 2 Diabetes Mellitus as Catalyst for Alzheimer's Disease

Completed

Conditions: Alzheimer´s Disease
Diabetes Mellitus Type 2

Interventions: Other: There is a retrospectiv observational study. No intervention

First Posted Date: 2015-07-17

Last Posted Date: 2017-04-12

Lead Sponsor: Hospital Universitari Vall d'Hebron Research Institute

Target Recruit Count: 202

Registration Number: NCT02501876

Locations: 🇪🇸
Vall d´Hebron University Hospital, Barcelona, Spain

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy